Drug Profile
Research programme: psoriasis therapeutics - Foamix/VIB
Latest Information Update: 16 Mar 2020
Price :
$50
*
At a glance
- Originator VIB
- Developer Foamix; VIB
- Class
- Mechanism of Action Caspase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 06 Jun 2013 Discontinued for Psoriasis in Belgium (Topical)
- 04 Feb 2009 Early research in Psoriasis in Belgium (Topical)